TG Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 233.66 million compared to USD 2.79 million a year ago. Net income was USD 12.67 million compared to net loss of USD 198.34 million a year ago.

Basic earnings per share from continuing operations was USD 0.09 compared to basic loss per share from continuing operations of USD 1.46 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to diluted loss per share from continuing operations of USD 1.46 a year ago.